the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04978753

Recruitment Status : Recruiting

First Posted : July 27, 2021

Last Update Posted : July 27, 2021

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Li-kun Chen, Sun Yat-sen University

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	May 30, 2022
Estimated Study Completion Date :	December 30, 2023

To Top